These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 22135044)

  • 1. Oral contraceptives decrease the prevalence of ovarian cancer in the hen.
    Treviño LS; Buckles EL; Johnson PA
    Cancer Prev Res (Phila); 2012 Feb; 5(2):343-9. PubMed ID: 22135044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral contraceptive use and impact of cumulative intake of estrogen and progestin on risk of ovarian cancer.
    Faber MT; Jensen A; Frederiksen K; Glud E; Høgdall E; Høgdall C; Blaakaer J; Kjaer SK
    Cancer Causes Control; 2013 Dec; 24(12):2197-206. PubMed ID: 24077761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. SHARE Study Group. Steroid Hormones and Reproductions.
    Ness RB; Grisso JA; Klapper J; Schlesselman JJ; Silberzweig S; Vergona R; Morgan M; Wheeler JE
    Am J Epidemiol; 2000 Aug; 152(3):233-41. PubMed ID: 10933270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk.
    Schildkraut JM; Calingaert B; Marchbanks PA; Moorman PG; Rodriguez GC
    J Natl Cancer Inst; 2002 Jan; 94(1):32-8. PubMed ID: 11773280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of estrogen and progestin potency of oral contraceptives with ovarian carcinoma risk.
    Lurie G; Thompson P; McDuffie KE; Carney ME; Terada KY; Goodman MT
    Obstet Gynecol; 2007 Mar; 109(3):597-607. PubMed ID: 17329510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent estrogen action was essential for maximal progestin effect in oral contraceptives.
    Bono Y; Kyo S; Kiyono T; Mizumoto Y; Nakamura M; Maida Y; Takakura M; Fujiwara H
    Fertil Steril; 2014 May; 101(5):1337-43. PubMed ID: 24656887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is progestin an independent risk factor for incident venous thromboembolism? A population-based case-control study.
    Barsoum MK; Heit JA; Ashrani AA; Leibson CL; Petterson TM; Bailey KR
    Thromb Res; 2010 Nov; 126(5):373-8. PubMed ID: 20833412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics of combined estrogen-progestin oral contraceptives 3. Inhibition of ovulation.
    Bastianelli C; Farris M; Rosato E; Brosens I; Benagiano G
    Expert Rev Clin Pharmacol; 2018 Nov; 11(11):1085-1098. PubMed ID: 30325245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exogenous progestins and breast cancer.
    Stanford JL; Thomas DB
    Epidemiol Rev; 1993; 15(1):98-107. PubMed ID: 8405216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence of a chemopreventive effect of progestin unrelated to ovulation on reproductive tract cancers in the egg-laying hen.
    Rodriguez GC; Barnes HJ; Anderson KE; Whitaker RS; Berchuck A; Petitte JN; Lancaster JM; Wenham RM; Turbov JM; Day R; Maxwell GL; Carver DK
    Cancer Prev Res (Phila); 2013 Dec; 6(12):1283-92. PubMed ID: 24136864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort.
    Lacey JV; Brinton LA; Leitzmann MF; Mouw T; Hollenbeck A; Schatzkin A; Hartge P
    J Natl Cancer Inst; 2006 Oct; 98(19):1397-405. PubMed ID: 17018786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral contraceptive and postmenopausal estrogen effects on lipoprotein triglyceride and cholesterol in an adult female population: relationships to estrogen and progestin potency.
    Knopp RH; Walden CE; Wahl PW; Hoover JJ; Warnick GR; Albers JJ; Ogilvie JT; Hazzard WR
    J Clin Endocrinol Metab; 1981 Dec; 53(6):1123-32. PubMed ID: 7298796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The adverse effects of hormonal therapy.
    Bush TL
    Cardiol Clin; 1986 Feb; 4(1):145-52. PubMed ID: 3518931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noncontraceptive health benefits of oral steroidal contraceptives.
    Mishell DR
    Am J Obstet Gynecol; 1982 Mar; 142(6 Pt 2):809-16. PubMed ID: 7065059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol.
    Wahl P; Walden C; Knopp R; Hoover J; Wallace R; Heiss G; Rifkind B
    N Engl J Med; 1983 Apr; 308(15):862-7. PubMed ID: 6572785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
    Menendez JA; Oza BP; Colomer R; Lupu R
    Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiologic aspects of exogenous progestagens in relation to their role in pathogenesis of human breast cancer.
    van Leeuwen FE
    Acta Endocrinol (Copenh); 1991; 125 Suppl 1():13-26. PubMed ID: 1801500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian cancer and menopausal hormone therapy in the NIH-AARP diet and health study.
    Trabert B; Wentzensen N; Yang HP; Sherman ME; Hollenbeck A; Danforth KN; Park Y; Brinton LA
    Br J Cancer; 2012 Sep; 107(7):1181-7. PubMed ID: 22929888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral contraception with estrogen and progestin combinations.
    Board JA
    Curr Ther Res Clin Exp; 1971 Jan; 13(1):1-5. PubMed ID: 4992561
    [No Abstract]   [Full Text] [Related]  

  • 20. Menopausal hormone replacement therapy and risk of ovarian cancer.
    Lacey JV; Mink PJ; Lubin JH; Sherman ME; Troisi R; Hartge P; Schatzkin A; Schairer C
    JAMA; 2002 Jul; 288(3):334-41. PubMed ID: 12117398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.